arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Pyxis Oncology, Inc.

PYXS

$1.61 ▼ -0.04 (-2.42%) at close

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Pyxis Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $100.1M

Dividend Yield —

Revenue Growth -14.2%

Op. Margin —

ROIC -160.9% ↘

FCF / Share $-1.02 ↘

Trailing P/E —

Price / Book 1.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$13.86M

↓ -14.2% —

Net Income Profit after all expenses

$-79.62M

↓ -3.0% —

FCF / Share Free cash flow per share

$-1.02

↓ -3.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-14.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-277%)	—	—	—	—	—	—
EPS Growth YoY (%)	3.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	28.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	49.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	59.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-3.0% Weak ↑ Weak Improving Year-over-year change in net income	-4.8% Weak ↑ Weak Improving Year-over-year change in net income	38.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-58.9% Weak Weak Year-over-year change in net income	-492.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-3.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	48.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	33.0% Excellent Excellent Year-over-year change in free cash flow	31.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-1.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	—	-478.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4091%)	—	—	—	—	—
FCF Margin (%) (%)	-458.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-358.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-160.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-51.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-60.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	65.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-92.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-127.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-149.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1094%)	-64.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-527%)	-58.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-491%)	-75.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-600%)	-29.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-294%)	82.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+447%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-927.69x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-8946.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	-82196.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-15.42M	$-19.47M	$-9.66M	$-179.29M	$-274.74M	$-8.08M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.22	$0.28	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.28	$-1.32	$-1.85	$-3.65	$-8.95	—	—
Free Cash Flow per Share (USD)	$-1.02	$-0.99	$-1.94	$-2.90	$-4.22	—	—
Book Value per Share (USD)	$0.85	$2.01	$2.81	$4.60	$8.11	$-12.13	—
Tangible Book Value per Share (USD)	$0.85	$1.97	$2.27	$4.60	$8.11	$-12.13	—
Basic Weighted Avg Shares (shares)	62.14M	58.45M	39.90M	33.03M	8.49M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$50.97M	$114.76M	$98.84M	$154.98M	$259.96M	$4.41M	—
Total Equity (USD)	$53.41M	$120.75M	$125.70M	$160.82M	$261.31M	$-15.64M	$-2.87M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$13.86M	$16.15M	—	—	—	—	—
Depreciation Expense (USD)	$4.51M	$2.98M	$1.93M	$709.00K	$647.00K	$469.00K	—
Net Income, GAAP (USD)	$-79.62M	$-77.33M	$-73.79M	$-120.72M	$-75.97M	$-12.83M	—
Operating Cash Flow (USD)	$-63.50M	$-57.67M	$-70.71M	$-89.33M	$-35.33M	$-10.08M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Pyxis Oncology, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PYXS with peers